Nurix Therapeutics (NRIX) EBITDA (2019 - 2026)

Nurix Therapeutics (NRIX) has reported EBITDA for 8 consecutive years, with -$94.2 million the latest figure, recorded in Q2 2026.

• In Q2 2026, EBITDA fell 94.95% year-over-year to -$94.2 million; the TTM figure through May 2026 stood at -$361.2 million (down 56.72% YoY), while the FY2025 annual figure was -$285.7 million, down 34.1% from the prior year.
• EBITDA eased to -$94.2 million in Q2 2026 per NRIX's latest filing, from -$92.5 million in the prior quarter.
• Across five years, EBITDA topped out at -$26.8 million in Q2 2023 and bottomed at -$94.2 million in Q2 2026.
• Historically, EBITDA has averaged -$56.9 million across 5 years, with a median of -$48.4 million in 2024.
• Annual changes were most pronounced in 2023 — EBITDA soared 41.45% — and 2026, when it plunged 94.95%.
• Nurix Therapeutics' EBITDA stood at -$48.7 million in 2022, then rose by 6.89% to -$45.3 million in 2023, then plunged by 42.62% to -$64.7 million in 2024, then decreased by 28.52% to -$83.1 million in 2025, then retreated by 13.37% to -$94.2 million in 2026.
• Business Quant data shows NRIX's EBITDA at -$94.2 million in Q2 2026, -$92.5 million in Q1 2026, and -$83.1 million in Q4 2025.